Neural Omega
HealthMaia ClinicalFor specialistsMaiaFor patients
ResearchMAR PlatformFor researchersMassaFor pharma
CompanyAboutTeam and missionMimicryThe scienceBioethicsHow we workObservatoryResearch
Contact
European autoimmune infrastructure

Decoding autoimmunity.

Neural Omega is rebuilding the infrastructure of autoimmune medicine — across patient care, clinical practice, research, and drug discovery. Four products. Two verticals. One European foundation.

4 products2 verticals1 foundation

A hundred diseases. One fragmented system.

Healthcare treats autoimmune disease as dozens of isolated conditions that don't share data, vocabulary, or infrastructure. Patients wait years for a diagnosis. Clinicians decide with partial information. Researchers work on cohorts too small to detect what matters. The same problem, seen from every angle.

4.5yrs
Average time from first symptoms to confirmed autoimmune diagnosis in Europe.
1in 12
People affected globally — yet most still navigate diagnosis and care alone.
500M+
Patients living with autoimmune conditions worldwide, most without adequate treatment.

Four products. Two verticals. One foundation.

A patient app, a clinical tool, a research platform and a drug discovery engine — operating on a single European data infrastructure. Each vertical has its own audience and its own roadmap. The architecture beneath them is one.

Four decisions that change what's possible.

The differentiators that no competitor based outside Europe can replicate with credibility — and that no generic healthtech platform has built into its foundation.

01

Apple-native, offline-first

Works where clinicians actually work — consultations without signal, hospitals with restricted networks, professional devices already in the healthcare ecosystem.

02

EHDS-ready by design

Built under GDPR. Aligned with FHIR and OMOP. Architected for the European Health Data Space coming into force in 2029. Not a retrofit — the foundation.

03

Clinical independence

Patient-facing and clinician-facing products take no pharma funding and sell no patient data. The patient and the clinician come first, always.

04

Built in Madrid, made for Europe

Spanish company. Madrid team. European infrastructure. Member of AseBio, backed by ENISA and NextGenerationEU.

Where medicine becomes infrastructure.

Read about Neural Omega

Pedro Bernardo Martín-Borregón, CEO, with a background in medicine and original research in bioinformatics, has seen first-hand how autoimmune patients move through the system, what clinicians actually need at the point of care, and where the data breaks down between specialties.

The technical foundation is being built alongside him by an engineering team that has chosen the Apple ecosystem and offline-first architecture as deliberate decisions, not defaults. Neural Omega is a member of AseBio and is backed by ENISA and NextGenerationEU under the Plan de Recuperación, Transformación y Resiliencia.

Founded
Madrid, 2025
Backed by
ENISA · NextGenEU
Member of
AseBio
Stage
Pre-commercial

One phenomenon. Four altitudes.

Molecular mimicry runs through the whole of autoimmune disease — from the person who lives it to the therapy that may one day correct it. One signal, read at four altitudes.

01Lives it.Patient
02Reads it.Clinician
03Models it.Researcher
04Harnesses it.Pharma
Follow the axis

Long-form thinking on autoimmune medicine.

We publish original research and analysis on the structural problems we're working to solve. Not marketing — thinking that gets cited.

Essay · No. 01March 2026

The diagnostic gap: why autoimmune patients still wait years for an answer

An examination of the structural reasons behind delayed autoimmune diagnosis in Europe — and what would have to change in the data layer of the health system to close it.

Read the essay →
See us in person

BioSpain 2026

If you want to see what we are building in person, meet the team, and discuss partnerships — this is where to find us.

Booth 122Bilbao Exhibition Centre29 Sep – 1 Oct 2026
Request a meeting